Novo's GLP-1 franchise (Ozempic, Wegovy) addresses a TAM in obesity that remains under-penetrated. Capacity constraints easing as Catalent acquisition integrates. CagriSema and oral semaglutide formulations defend against Lilly competition. After share correction, valuation more reasonable. Long-duration compounder with structural tailwinds.
Thesis reviewed May 29, 2026
Novo Nordisk A/S is headquartered in Denmark, which is currently showing moderate signals.
π©π°Denmark55NEUTRALView Denmark risk detail βπPharma0NEUTRAL| Ticker | Company | Score | Gap | Signal Ξ | Action |
|---|---|---|---|---|---|
| SNY | Sanofi | 50 | +14% | β0% | EARLY |
| AZN | AstraZeneca PLC | 50 | +11% | β0% | EARLY |
| TAK | Takeda Pharmaceutical Company Limited | 50 | +10% | β0% | NEUTRAL |
| LLY | Eli Lilly and Company | 50 | +24% | β0% | EARLY |
| NVO | Novo Nordisk A/S | 50 | +15% | β0% | EARLY |
| REGN | Regeneron Pharmaceuticals Inc. | 50 | -16% | β0% | AVOID |
| RDY | Dr Reddy's Laboratories Ltd | 48 | +7% | β0% | NEUTRAL |
Investors who hold NVO may also have indirect exposure through these country funds.
CagriSema Phase 3 results competitive vs Lilly
Wegovy supply constraints fully resolved
EU obesity treatment guidelines update
Estimates Β· Yahoo Finance Β· Not audited figures
| Politician | Party | Type | Amount | Trade Date | Return |
|---|---|---|---|---|---|
| John JamesMI | R | Buy | $1kβ$15k | Sep 4, 24 | -63.0% |
| John JamesMI | R | Buy | $1kβ$15k | Nov 10, 23 | -65.1% |